Merck’s NDA for Isentress has been accepted by the FDA. Data in the NDA support the proposed use of Isentress in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The priority review status is a designation for investigational products that address unmet medical needs. The FDA is expected to review and act on the NDA within six months of submissi...